CytoDyn president takes medical leave; CFO assumes interim role; new CMO and advisor appointed

CytoDyn Inc.

Dr. Cyrus Arman, President, takes medical leave; Antonio Migliarese (CFO) named interim principal executive officer.
Dr. Melissa Palmer appointed interim Chief Medical Officer; she has NASH and liver disease expertise.
Dr. Salah Kivlighn joins as clinical and strategic advisor; 30+ years industry experience including at Merck and Kite Pharma.
Company priorities: lift HIV clinical hold on leronlimab, advance NASH phase 2b trial, explore strategic opportunities.

item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed (interim)

Antonio Migliarese

acting principal executive officer

CYDY · CytoDyn Inc.

Effective: 2023-05-18
Filed: May 24, 2023, 7:59 PM ET

On May 18, 2023, the Company’s Board of Directors appointed Antonio Migliarese as acting principal executive officer of the Company on an interim basis.

Role change

Dr. Cyrus Arman

President

CYDY · CytoDyn Inc.

Effective: 2023-05-18
Filed: May 24, 2023, 7:59 PM ET

Dr. Cyrus Arman, President of CytoDyn Inc. (the “Company”) and the Company’s principal executive officer, recently informed the Company that he will be taking a medical leave of absence.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Antonio Migliarese was appointed as acting principal executive officer at CytoDyn Inc..

Action: appointed
Role: acting principal executive officer

Exact text from the filing

On May 18, 2023, the Company’s Board of Directors appointed Antonio Migliarese as acting principal executive officer of the Company on an interim basis.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.9

Dr. Cyrus Arman changed role as President at CytoDyn Inc..

Action: taking a medical leave of absence
Role: President

Exact text from the filing

Dr. Cyrus Arman, President of CytoDyn Inc. (the “Company”) and the Company’s principal executive officer, recently informed the Company that he will be taking a medical leave of absence.

View on SEC.gov

CytoDyn Inc. filing history →

Source: SEC EDGAR

accession 0001558370-23-010412

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.